Boehringer Ingelheim is very proud to be one of the major sponsors of the first National Mastitis Council (NMC) meeting to be held in Europe, where it will present two posters on Ubrolexin®.
The first poster was written in collaboration with Sofie Piepers from the M-team, at the University of Ghent. The poster considers a report of a field trial of Ubrolexin® conducted in Spain, The Netherlands and Belgium.
All cases included in the study were farmer-diagnosed, natural occurrences of clinical mastitis on commercial dairy farms. All cows were treated intramammarily once a day with Ubrolexin®. In total, 1184 cows were enrolled in the study. Overall clinical cure was 80.3%. Of 546 and 591 cows, both pre- and post-treatment milk samples were available for bacteriological culturing and somatic cell counting, respectively. The overall bacteriological cure rate and somatic cell count cure rate were 71.1% and 64.3%, respectively.
... To read this complete article you need a Premium or Digital subscription Subscribe & login and you will be able to continue your reading * M2-premium – digital + print (€ 90 /year) * M2 – digital (€ 40 /year)